- |||||||||| Ansimar (doxofylline) / ICE GROUP, Alitair Pharma
Journal: Development of a rapid method for the simultaneous determination of aminophylline, doxofylline, bromhexine, and ambroxol by HPLC. (Pubmed Central) - Nov 4, 2024 The established HPLC method is simple, reliable, and stable, allowing for the simultaneous determination of the four antitussive and expectorant drugs. APL, DXL, BXH, and AXH were stable within 48 hours when mixed with 0.9% sodium chloride and 5% glucose injections.
- |||||||||| Ansimar (doxofylline) / ICE GROUP, Alitair Pharma
Retrospective data, Review, Journal: Efficacy and safety profile of doxofylline in asthma: a meta-analysis. (Pubmed Central) - Sep 12, 2024 Subgroup analysis results indicated that the improvement in FEV1 with doxofylline combined with budesonide was superior to that of budesonide combined with montelukast or tiotropium but inferior to that of budesonide plus formoterol combination. Doxofylline treatment significantly reduces the risk of asthma events and adverse events (AEs), demonstrating good safety and longer-term benefits.
- |||||||||| Bactek (MV130) / Inmunotek, Erdotin (erdosteine) / Recipharm, Alitair Pharma, Daewoong Pharma, Stiolto Respimat (olodaterol/tiotropium FDC) / Boehringer Ingelheim
BRONCHIECTASIS AND POTENTIAL BENEFIT OF MUCOSAL VACCINE (Convention Center Exhibit Hall: Poster Area 1) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6304; The last infectious exacerbation was on January 2023 treated with ciprofloxacin 500 mgs bid for 2 weeks...We starting management based on dual bronchodilation (Tiotropium + Olodaterol), mucolytic (erdosteine) and immunotherapy with MV130, 2 sublingual shots OD for three months...By November 2023 she visited emergency department due to a new recurrence treated with amoxicillin/clavulanate... Clinical trials are needed to clear expectations of the mucosal vaccines in the bronchiectasis field.
- |||||||||| Erdotin (erdosteine) / Recipharm, Alitair Pharma, Daewoong Pharma
Improvement of Severe Scleroderma Cases with Lung and Heart Involvement Treated Using Methotrexat (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2506; However, in the observations on patients for 1 month after therapy showed improvement of the condition of skin stiffness and reduced shortness of breath. MTX accompanied by systemic corticosteroids can be an inexpensive treatment option even in severe scleroderma conditions.
- |||||||||| Ansimar (doxofylline) / ICE GROUP, Alitair Pharma
Review, Journal: A narrative review of theophylline: is there still a place for an old friend? (Pubmed Central) - Jun 17, 2024 Moreover, we also aim to determine if there is a rationale for using low-dose theophylline due to its immunomodulatory and anti-inflammatory effect, or if the future of methylxanthines lies in newly synthesized derivates of theophylline such as bamifylline, or doxofylline...We searched the database since the year 2009 using the MeSH terms "theophylline", "aminophylline", and "methylxanthines" and we included original articles in the English language...There is considerable controversy associated with its use in current medicine, which can be attributed both to its narrow therapeutic range and its mentioned cardiotoxic effect. Herein, we summarize the current state-of-art of theophylline and its use in human medicine.
- |||||||||| Erdotin (erdosteine) / Recipharm, Alitair Pharma, Daewoong Pharma
Effect of 5 years of treatment with mucoactive drugs on COPD exacerbations in the Czech Republic: a real-life study (PS-11; Poster board no. 12) - May 31, 2024 - Abstract #ERS2024ERS_4736; The use of mucoactive treatment for two years showed a statistically significant reduction in the number of COPD exacerbations over the five years, for both all exacerbations and moderate exacerbations. The reduction in exacerbations was more pronounced in patients with cough and in patients with stage 3 to 4 COPD and was independent of the use of ICS.
- |||||||||| Erdotin (erdosteine) / Recipharm, Alitair Pharma, Daewoong Pharma
The effectiveness of erdosteine in patients with COPD in combination with secondary bronchiectasis (PS-1; Poster board no. 7) - May 31, 2024 - Abstract #ERS2024ERS_1126; Conclusion. Added erdosteine to the basic therapy leads to a reduction in the duration of AE of COPD plus BE and also leads to a decrease in the levels of CRP, both at the onset of the remission phase and on the 30th day of therapy compared to patients who as basic therapy received LAMA/LABA/ICS
- |||||||||| Ansimar (doxofylline) / ICE GROUP, Alitair Pharma
Journal: Doxofylline as a steroid-sparing treatment in Mexican children with asthma. (Pubmed Central) - May 7, 2024 Rescue medication use decreased significantly in patients receiving D?+?SDB during the first 4-week period. Our results suggest that doxofylline may be a steroid-sparing treatment in asthma, but longer-term, controlled studies are needed to confirm these observations.
- |||||||||| Ansimar (doxofylline) / ICE GROUP, Alitair Pharma, Januvia (sitagliptin) / Merck (MSD)
Journal: Biochemical evaluation and ligand binding studies on glycerophosphodiester phosphodiesterase from Staphylococcus aureus using STD-NMR spectroscopy and molecular docking analysis. (Pubmed Central) - Feb 19, 2024 After the onset of COPD, doxofylline treatment can achieve better effects than aminophylline treatment. In this study, competent E. coli BL21(DE3)pLysS expression cells were used to express the GDPD enzyme from vancomycin-resistant Staphylococcus aureus (VRSA), which was then purified using size exclusion and anion exchange chromatography...Out of 79 drugs, 13 drugs, including tenofovir (1), adenosine (2), clioquinol (11), bromazepam (12), lamotrigine (13), sulfadiazine (14), azathioprine (15), nicotine (16), sitagliptin PO4 (17), doxofylline (18), clindamycin phosphate (19), gentamycin sulphate (20), and ceftriaxone sodium (21) revealed varying degrees of inhibitory potential with IC50 values in the range of 400
- |||||||||| Erdotin (erdosteine) / Recipharm, Alitair Pharma, Daewoong Pharma
Journal: Acute bronchitis - modern possibilities of mucactive therapy (Pubmed Central) - Jan 6, 2024 The use of erdosteine was accompanied by a significant mucoactive effect in the form of a pronounced regression of cough in patients with ?? compared to the comparison group in shorter term.
- |||||||||| Ansimar (doxofylline) / ICE GROUP, Alitair Pharma
Bronchodilator effect of oral doxofylline and procaterol in asthma: a randomized crossover study (PS-8 in poster area) - Jun 17, 2023 - Abstract #ERS2023ERS_3761; Public health; General respiratory patient care; Cell and molecular biology; Physiology; Imaging; Pulmonary function testing; Respiratory intensive care Epidemiology; General respiratory patient care; Cell and molecular biology; Imaging; Physiology; Pulmonary function testing
- |||||||||| Erdotin (erdosteine) / Recipharm, Alitair Pharma, Daewoong Pharma
Antiviral and anti-inflammatory effects of Erdosteine and MET-1 in SARS-CoV-2 in vitro infection (PS-14 in poster area) - Jun 17, 2023 - Abstract #ERS2023ERS_1786; Epidemiology; General respiratory patient care; Cell and molecular biology; Imaging; Physiology; Pulmonary function testing Pulmonary function testing; Respiratory intensive care; Public health; Epidemiology; General respiratory patient care; Cell and molecular biology
- |||||||||| Erdotin (erdosteine) / Recipharm, Alitair Pharma, Daewoong Pharma
Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: A systematic review and meta-analysis (Westminster, 4th floor) - Nov 15, 2022 - Abstract #BTSWM2022BTS_WM_247; Mucolytics were also associated with a modest beneficial impact on the partial pressure of oxygen in arterial blood (MD 3.21 [1.51, 4.92], I2= 38%) and oxygen saturation (MD 0.96 [0.27, 1.66], I2= 0%).Conclusions Overall, we found moderate-certainty evidence that mucolytics improve symptoms and treatment success rate in COPD exacerbations. These benefits may be potentiated in patients exerting sputum hypersecretion with increased viscosity; however, we were not able to assess this subgroup in the absence of adequate data.
- |||||||||| Erdotin (erdosteine) / Recipharm, Alitair Pharma, Daewoong Pharma
Late Breaking Abstract - Impact of erdosteine on exacerbations in moderate COPD (TP-26 in thematic poster area) - Aug 1, 2022 - Abstract #ERS2022ERS_5078; In GOLD 2 patients erdosteine decreased the frequency and changed the treatment of exacerbations, lessening their impact. Preventing exacerbations in moderate COPD produces clinically meaningful benefits.
- |||||||||| Erdotin (erdosteine) / Recipharm, Alitair Pharma, Daewoong Pharma
Late Breaking Abstract - Health economic implications of the use of erdosteine in patients with chronic obstructive lung disease. (TP-2 in thematic poster area) - Aug 1, 2022 - Abstract #ERS2022ERS_5019; Considering COPD prevalence for the selected Countries, erdosteine could be associated with a reduction in the number of hospitalizations per Country/year up to about 88,000 corresponding to an annual saving up to €75 millions. Conclusions The treatment with erdosteine can be considered as an option to contribute to the reduction in COPD related hospitalizations and costs in charge to NHS
- |||||||||| Erdotin (erdosteine) / Recipharm, Alitair Pharma, Daewoong Pharma
Review, Journal: Reactive Sulfur Compounds in the Fight against COVID-19. (Pubmed Central) - Jun 25, 2022 Due to their documented anti-inflammatory, antioxidant, and antiviral effects, reactive sulfur compounds, including hydrogen sulfide (HS), lipoic acid (LA), N-acetylcysteine (NAC), glutathione (GSH), and some other lesser-known sulfur compounds, have attracted the interest of scientists for the treatment and prevention of the adverse effects of diseases caused by SARS-CoV-2. This article reviews current knowledge about various endogenous or exogenous reactive sulfur compounds and discusses the possibility, or in some cases the results, of their use in the treatment or prophylaxis of COVID-19.
- |||||||||| Erdotin (erdosteine) / Recipharm, Alitair Pharma, Daewoong Pharma
Preclinical, Journal: The protective effects of erdosteine on subacute diazinon-induced oxidative stress and inflammation in rats. (Pubmed Central) - Mar 23, 2022 Conclusively, besides the known mucolytic efficacy of ERDOS, it may also be stated to display free radical scavenger, antioxidant, and anti-inflammatory characteristics to inhibit some proinflammatory cytokines that are specifically involved in oxidative stress. Additionally, the ameliorating property of ERDOS can be benefited from in possible DZN-induced toxication cases.
- |||||||||| Erdotin (erdosteine) / Recipharm, Alitair Pharma, Daewoong Pharma
Journal: Erdosteine enhances antibiotic activity against bacteria within biofilm. (Pubmed Central) - Mar 16, 2022 Similar results were seen for amoxicillin/clavulanate and levofloxacin against 6-h MSSA biofilms...These results suggest that erdosteine enhances the activity of the antibiotic by facilitating its penetration into biofilms and by disrupting the extracellular polymeric substance matrix; this should be confirmed with further studies. The potential clinical value of erdosteine in treating biofilm-related infections warrants further investigation.
- |||||||||| Erdotin (erdosteine) / Recipharm, Alitair Pharma, Daewoong Pharma
Preclinical, Journal: The influence of erdosteine administration on lead-induced oxidative stress in rat muscle. (Pubmed Central) - Feb 3, 2022 The activities of glutathione-S-transferase (GST) were significantly lower in group II and significantly higher in groups VI and VII compared to the control group, while the activities of glutathione reductase (GR) were significantly lower in group III and significantly higher in group VI. Erdosteine has an effect of protection against lead-induced oxidative stress which is not worse than that of EDTA.
- |||||||||| Erdotin (erdosteine) / Recipharm, Alitair Pharma, Daewoong Pharma
Preclinical, Journal, IO biomarker: Effect of Erdosteine on Middle Ear Effusion in Rats by Mediating TLR4 Signaling Pathway. (Pubmed Central) - Jan 26, 2022 In addition, the protein assay results revealed that the protein levels of TLR4 and JNK were evidently increased in the model group. Erdosteine can treat the middle ear effusion in rats by repressing the activation of the TLR4 signaling pathway.
|